These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

2433 related articles for article (PubMed ID: 18519975)

  • 1. Molecular control of lymphatic metastasis.
    Achen MG; Stacker SA
    Ann N Y Acad Sci; 2008; 1131():225-34. PubMed ID: 18519975
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Expression of VEGF-C and VEGF-D as significant markers for assessment of lymphangiogenesis and lymph node metastasis in non-small cell lung cancer.
    Feng Y; Wang W; Hu J; Ma J; Zhang Y; Zhang J
    Anat Rec (Hoboken); 2010 May; 293(5):802-12. PubMed ID: 20225197
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lymphangiogenesis and its relationship with lymphatic metastasis and prognosis in malignant melanoma.
    Liu B; Ma J; Wang X; Su F; Li X; Yang S; Ma W; Zhang Y
    Anat Rec (Hoboken); 2008 Oct; 291(10):1227-35. PubMed ID: 18561194
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tumor-secreted vascular endothelial growth factor-C is necessary for prostate cancer lymphangiogenesis, but lymphangiogenesis is unnecessary for lymph node metastasis.
    Wong SY; Haack H; Crowley D; Barry M; Bronson RT; Hynes RO
    Cancer Res; 2005 Nov; 65(21):9789-98. PubMed ID: 16267000
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differential expression of VEGF ligands and receptors in prostate cancer.
    Woollard DJ; Opeskin K; Coso S; Wu D; Baldwin ME; Williams ED
    Prostate; 2013 May; 73(6):563-72. PubMed ID: 23038639
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tumor-induced lymphangiogenesis: a target for cancer therapy?
    Thiele W; Sleeman JP
    J Biotechnol; 2006 Jun; 124(1):224-41. PubMed ID: 16497404
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Stage-specific characterization of the vascular endothelial growth factor axis in prostate cancer: expression of lymphangiogenic markers is associated with advanced-stage disease.
    Kaushal V; Mukunyadzi P; Dennis RA; Siegel ER; Johnson DE; Kohli M
    Clin Cancer Res; 2005 Jan; 11(2 Pt 1):584-93. PubMed ID: 15701844
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The tyrosine kinase inhibitor cediranib blocks ligand-induced vascular endothelial growth factor receptor-3 activity and lymphangiogenesis.
    Heckman CA; Holopainen T; Wirzenius M; Keskitalo S; Jeltsch M; Ylä-Herttuala S; Wedge SR; Jürgensmeier JM; Alitalo K
    Cancer Res; 2008 Jun; 68(12):4754-62. PubMed ID: 18559522
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differential in vivo and in vitro expression of vascular endothelial growth factor (VEGF)-C and VEGF-D in tumors and its relationship to lymphatic metastasis in immunocompetent rats.
    Krishnan J; Kirkin V; Steffen A; Hegen M; Weih D; Tomarev S; Wilting J; Sleeman JP
    Cancer Res; 2003 Feb; 63(3):713-22. PubMed ID: 12566318
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vascular endothelial growth factor-C and C-C chemokine receptor 7 in tumor cell-lymphatic cross-talk promote invasive phenotype.
    Issa A; Le TX; Shoushtari AN; Shields JD; Swartz MA
    Cancer Res; 2009 Jan; 69(1):349-57. PubMed ID: 19118020
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expression of vascular endothelial growth factor receptor-3 by lymphatic endothelial cells is associated with lymph node metastasis in prostate cancer.
    Zeng Y; Opeskin K; Baldwin ME; Horvath LG; Achen MG; Stacker SA; Sutherland RL; Williams ED
    Clin Cancer Res; 2004 Aug; 10(15):5137-44. PubMed ID: 15297417
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tumor and lymph node lymphangiogenesis--impact on cancer metastasis.
    Tobler NE; Detmar M
    J Leukoc Biol; 2006 Oct; 80(4):691-6. PubMed ID: 16793912
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pathways targeting tumor lymphangiogenesis.
    Wissmann C; Detmar M
    Clin Cancer Res; 2006 Dec; 12(23):6865-8. PubMed ID: 17145802
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expression of vascular endothelial growth factors A, B, C, and D and their relationships to lymph node status in lung adenocarcinoma.
    Niki T; Iba S; Tokunou M; Yamada T; Matsuno Y; Hirohashi S
    Clin Cancer Res; 2000 Jun; 6(6):2431-9. PubMed ID: 10873096
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Expression and clinical significance of vascular endothelial growth factor C and vascular endothelial growth factor receptor 3 in non-small cell lung carcinoma].
    Lu ZQ; Li HG; Xie DR; Zhang HZ; Shen XM; Zeng YJ; Zeng H
    Ai Zheng; 2005 Sep; 24(9):1132-5. PubMed ID: 16159440
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Expression of vascular endothelial growth factors (VEGF)-A, -C and -D and their prognostic significance and relationship with angio- and lymphangiogenesis in gastric cancer].
    Wang XL; Ai ZS; Fang JP; Tang RY; Chen XM
    Zhonghua Zhong Liu Za Zhi; 2008 Nov; 30(11):837-43. PubMed ID: 19173829
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vascular endothelial growth factor-D induces lymphangiogenesis and lymphatic metastasis in models of ductal pancreatic cancer.
    Von Marschall Z; Scholz A; Stacker SA; Achen MG; Jackson DG; Alves F; Schirner M; Haberey M; Thierauch KH; Wiedenmann B; Rosewicz S
    Int J Oncol; 2005 Sep; 27(3):669-79. PubMed ID: 16077915
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tumor lymphangiogenesis and melanoma metastasis.
    Rinderknecht M; Detmar M
    J Cell Physiol; 2008 Aug; 216(2):347-54. PubMed ID: 18481261
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vascular endothelial growth factor-C and its receptor VEGFR-3 in non-small-cell lung cancer: concurrent expression in cancer cells from primary tumour and metastatic lymph node.
    Saintigny P; Kambouchner M; Ly M; Gomes N; Sainte-Catherine O; Vassy R; Czernichow S; Letoumelin P; Breau JL; Bernaudin JF; Kraemer M
    Lung Cancer; 2007 Nov; 58(2):205-13. PubMed ID: 17686546
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of VEGFR-3 activation with the antagonistic antibody more potently suppresses lymph node and distant metastases than inactivation of VEGFR-2.
    Roberts N; Kloos B; Cassella M; Podgrabinska S; Persaud K; Wu Y; Pytowski B; Skobe M
    Cancer Res; 2006 Mar; 66(5):2650-7. PubMed ID: 16510584
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 122.